Bone Health in Oncology: Closing Gaps, Reducing Costs, and Unlocking Biosimilar Value

Why It Matters

Bone health directly influences survival, quality of life, and payer budgets, making it a critical yet under‑addressed component of cancer care. Leveraging biosimilars can reduce expenditures while improving patient outcomes.

Key Takeaways

• Early bone-modifying agent use cuts fracture risk dramatically
• Biosimilars lower BMA costs, enabling broader patient access
• Skeletal events raise breast cancer mortality up to 52%
• Guideline adherence improves detection, reduces costly hospitalizations
• High out‑of‑pocket BMA prices cause treatment delays

Pulse Analysis

The burden of skeletal complications in oncology extends far beyond pain, driving mortality spikes and inflating health‑care spending. Patients with breast or prostate cancer face fracture risks that can double or triple death rates, while hip‑fracture mortality in the U.S. hovers around 21% within a year. These events trigger costly hospital admissions, surgeries, and long‑term care, straining both insurers and patients. Early identification through DEXA scans and proactive prescribing of bone‑modifying agents (BMAs) are proven to curb these outcomes, yet real‑world utilization remains suboptimal.

Biosimilars emerge as a pragmatic lever to bridge the treatment gap. By introducing competitive pricing, they have already generated billions in oncology savings and can shave $23‑$56 million from a one‑million‑member health plan over five years for denosumab alone. This price compression enables earlier BMA initiation, reduces out‑of‑pocket expenses, and supports broader adoption without compromising efficacy. Moreover, favorable formulary tiering amplifies these gains, allowing health systems to reinvest savings into supportive‑care services and patient education, ultimately lowering the incidence of skeletal‑related events.

Strategically, health‑care leaders should embed bone health into standard oncology pathways, mandating baseline DEXA assessments and routine BMA reviews. Multidisciplinary teams—including oncologists, primary care physicians, endocrinologists, and supportive‑care specialists—must coordinate to ensure timely therapy and monitor for rebound fractures when denosumab is discontinued. Coupled with payer policies that prioritize biosimilar coverage, these actions can transform bone health from a reactive concern into a proactive, cost‑effective pillar of cancer care, delivering measurable improvements in survival and quality of life.